A citation-based method for searching scientific literature

Chiara Macchi, Nicola Ferri, Cesare R Sirtori, Alberto Corsini, Maciej Banach, Massimiliano Ruscica. Am J Pathol 2021
Times Cited: 24







List of co-cited articles
173 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
37

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Marianne Abifadel, Mathilde Varret, Jean-Pierre Rabès, Delphine Allard, Khadija Ouguerram, Martine Devillers, Corinne Cruaud, Suzanne Benjannet, Louise Wickham, Danièle Erlich,[...]. Nat Genet 2003
33

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
33

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
29

PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.
Zhiyong Qi, Liang Hu, Jianjun Zhang, Wenlong Yang, Xin Liu, Daile Jia, Zhifeng Yao, Lin Chang, Guanxing Pan, Haoxuan Zhong,[...]. Circulation 2021
33
25

PCSK9: a key modulator of cardiovascular health.
Nabil G Seidah, Zuhier Awan, Michel Chrétien, Majambu Mbikay. Circ Res 2014
359
20

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
Jonathan C Cohen, Eric Boerwinkle, Thomas H Mosley, Helen H Hobbs. N Engl J Med 2006
20

PCSK9 induces a pro-inflammatory response in macrophages.
Chiara Ricci, Massimiliano Ruscica, Marina Camera, Laura Rossetti, Chiara Macchi, Alessandra Colciago, Ilaria Zanotti, Maria Giovanna Lupo, Maria Pia Adorni, Arrigo F G Cicero,[...]. Sci Rep 2018
98
20

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
Nicola Ferri, Gianpaolo Tibolla, Angela Pirillo, Francesco Cipollone, Andrea Mezzetti, Stefano Pacia, Alberto Corsini, Alberico Luigi Catapano. Atherosclerosis 2012
160
20

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Ahmed Zaid, Anna Roubtsova, Rachid Essalmani, Jadwiga Marcinkiewicz, Ann Chamberland, Josée Hamelin, Michel Tremblay, Hélène Jacques, Weijun Jin, Jean Davignon,[...]. Hepatology 2008
277
20

Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
Massimiliano Ruscica, Chiara Ricci, Chiara Macchi, Paolo Magni, Riccardo Cristofani, Jingwen Liu, Alberto Corsini, Nicola Ferri. J Biol Chem 2016
72
20

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.
Zhenze Zhao, Yetsa Tuakli-Wosornu, Thomas A Lagace, Lisa Kinch, Nicholas V Grishin, Jay D Horton, Jonathan C Cohen, Helen H Hobbs. Am J Hum Genet 2006
439
16

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Eric Bruckert, Robert A Hegele, Ronald M Krauss, Frederick J Raal, Heribert Schunkert,[...]. Eur Heart J 2017
16

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.
Amanda J Hooper, A David Marais, Donald M Tanyanyiwa, John R Burnett. Atherosclerosis 2007
251
16

In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.
Kiran Musunuru, Alexandra C Chadwick, Taiji Mizoguchi, Sara P Garcia, Jamie E DeNizio, Caroline W Reiss, Kui Wang, Sowmya Iyer, Chaitali Dutta, Victoria Clendaniel,[...]. Nature 2021
76
16

Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Hagai Tavori, Ilaria Giunzioni, Irene M Predazzi, Deanna Plubell, Anna Shivinsky, Joshua Miles, Rachel M Devay, Hong Liang, Shirya Rashid, MacRae F Linton,[...]. Cardiovasc Res 2016
56
16

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
Karin Leander, Anders Mälarstig, Ferdinand M Van't Hooft, Craig Hyde, Mai-Lis Hellénius, Jason S Troutt, Robert J Konrad, John Öhrvik, Anders Hamsten, Ulf de Faire. Circulation 2016
119
16

The biology and therapeutic targeting of the proprotein convertases.
Nabil G Seidah, Annik Prat. Nat Rev Drug Discov 2012
482
16

Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.
Xinjian Liu, Xuhui Bao, Mengjie Hu, Hanman Chang, Meng Jiao, Jin Cheng, Liyi Xie, Qian Huang, Fang Li, Chuan-Yuan Li. Nature 2020
57
16

Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice.
Paul F Lebeau, Jae Hyun Byun, Khrystyna Platko, Ali A Al-Hashimi, Šárka Lhoták, Melissa E MacDonald, Aurora Mejia-Benitez, Annik Prat, Suleiman A Igdoura, Bernardo Trigatti,[...]. JHEP Rep 2019
26
16

Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
Paul M Ridker, Nader Rifai, Gary Bradwin, Lynda Rose. Eur Heart J 2016
63
16

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.
Arturo Cesaro, Vanessa Bianconi, Felice Gragnano, Elisabetta Moscarella, Fabio Fimiani, Emanuele Monda, Olga Scudiero, Giuseppe Limongelli, Matteo Pirro, Paolo Calabrò. Biofactors 2020
30
16

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Jennifer G Robinson, Michel Farnier, Michel Krempf, Jean Bergeron, Gérald Luc, Maurizio Averna, Erik S Stroes, Gisle Langslet, Frederick J Raal, Mahfouz El Shahawy,[...]. N Engl J Med 2015
16

Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9: The Role of STAT3.
Chiara Macchi, Maria Francesca Greco, Margherita Botta, Paola Sperandeo, Paola Dongiovanni, Luca Valenti, Arrigo F G Cicero, Claudio Borghi, Maria Giovanna Lupo, Stefano Romeo,[...]. Am J Pathol 2020
15
26

Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals.
Chiara Macchi, Nicola Ferri, Chiara Favero, Laura Cantone, Luisella Vigna, Angela C Pesatori, Maria G Lupo, Cesare R Sirtori, Alberto Corsini, Valentina Bollati,[...]. Eur J Prev Cardiol 2019
27
16

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Kausik K Ray, R Scott Wright, David Kallend, Wolfgang Koenig, Lawrence A Leiter, Frederick J Raal, Jenna A Bisch, Tara Richardson, Mark Jaros, Peter L J Wijngaard,[...]. N Engl J Med 2020
237
16

Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis.
Dhruva J Dwivedi, Peter M Grin, Momina Khan, Annik Prat, Ji Zhou, Alison E Fox-Robichaud, Nabil G Seidah, Patricia C Liaw. Shock 2016
71
12


Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta.
Zufeng Ding, Shijie Liu, Xianwei Wang, Xiaoyan Deng, Yubo Fan, Changqing Sun, Yannian Wang, Jawahar L Mehta. Antioxid Redox Signal 2015
101
12

PCSK9: a convertase that coordinates LDL catabolism.
Jay D Horton, Jonathan C Cohen, Helen H Hobbs. J Lipid Res 2009
399
12

PCSK9 is a critical regulator of the innate immune response and septic shock outcome.
Keith R Walley, Katherine R Thain, James A Russell, Muredach P Reilly, Nuala J Meyer, Jane F Ferguson, Jason D Christie, Taka-aki Nakada, Chris D Fjell, Simone A Thair,[...]. Sci Transl Med 2014
211
12

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels.
Tanja Rothgangl, Melissa K Dennis, Paulo J C Lin, Rurika Oka, Dominik Witzigmann, Lukas Villiger, Weihong Qi, Martina Hruzova, Lucas Kissling, Daniela Lenggenhager,[...]. Nat Biotechnol 2021
42
12

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.
Suzanne Benjannet, David Rhainds, Rachid Essalmani, Janice Mayne, Louise Wickham, Weijun Jin, Marie-Claude Asselin, Josée Hamelin, Mathilde Varret, Delphine Allard,[...]. J Biol Chem 2004
452
12

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Frederick J Raal, David Kallend, Kausik K Ray, Traci Turner, Wolfgang Koenig, R Scott Wright, Peter L J Wijngaard, Danielle Curcio, Mark J Jaros, Lawrence A Leiter,[...]. N Engl J Med 2020
158
12

PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages.
Zufeng Ding, Shijie Liu, Xianwei Wang, Sue Theus, Xiaoyan Deng, Yubo Fan, Sichang Zhou, Jawahar L Mehta. Cardiovasc Res 2018
43
12

Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.
Anna Roubtsova, Mercedes Nancy Munkonda, Zuhier Awan, Jadwiga Marcinkiewicz, Ann Chamberland, Claude Lazure, Katherine Cianflone, Nabil G Seidah, Annik Prat. Arterioscler Thromb Vasc Biol 2011
179
12

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Maryssa Canuel, Xiaowei Sun, Marie-Claude Asselin, Eustache Paramithiotis, Annik Prat, Nabil G Seidah. PLoS One 2013
140
12

Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines.
Shijie Liu, Xiaoyan Deng, Peng Zhang, Xianwei Wang, Yubo Fan, Sichang Zhou, Shengyu Mu, Jawahar L Mehta, Zufeng Ding. Cardiovasc Res 2020
17
17

PCSK9 as a Positive Modulator of Platelet Activation.
Marina Camera, Laura Rossetti, Silvia S Barbieri, Ilaria Zanotti, Barbara Canciani, Daniela Trabattoni, Massimiliano Ruscica, Elena Tremoli, Nicola Ferri. J Am Coll Cardiol 2018
34
12

Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Hyun-Duk Jang, Sang Eun Lee, Jimin Yang, Hyun-Chae Lee, Dasom Shin, Hwan Lee, Jaewon Lee, Sooryeonhwa Jin, Soungchan Kim, Seung Ji Lee,[...]. Eur Heart J 2020
28
12

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.
Nabil G Seidah, Suzanne Benjannet, Louise Wickham, Jadwiga Marcinkiewicz, Stephanie Belanger Jasmin, Stefano Stifani, Ajoy Basak, Annik Prat, Michel Chretien. Proc Natl Acad Sci U S A 2003
805
12



The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease.
Sha Li, Cheng-Gang Zhu, Yuan-Lin Guo, Rui-Xia Xu, Yan Zhang, Jing Sun, Jian-Jun Li. J Atheroscler Thromb 2015
32
12

PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction.
Hua Sun, Ronald M Krauss, Jeffrey T Chang, Ba-Bie Teng. J Lipid Res 2018
42
12

Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice.
Marie-Line Peyot, Anna Roubtsova, Roxane Lussier, Ann Chamberland, Rachid Essalmani, S R Murthy Madiraju, Nabil G Seidah, Marc Prentki, Annik Prat. Biochim Biophys Acta Mol Cell Biol Lipids 2021
9
33

Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.
Simon Glerup, Rainer Schulz, Ulrich Laufs, Klaus-Dieter Schlüter. Basic Res Cardiol 2017
49
12

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Amand F Schmidt, Lucy S Pearce, John T Wilkins, John P Overington, Aroon D Hingorani, Juan P Casas. Cochrane Database Syst Rev 2017
87
12

Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study.
Nicola Ferri, Massimiliano Ruscica, Daniela Coggi, Alice Bonomi, Mauro Amato, Beatrice Frigerio, Daniela Sansaro, Alessio Ravani, Fabrizio Veglia, Nicolò Capra,[...]. Atherosclerosis 2020
8
37

NLRP3 inflammasome via IL-1β regulates PCSK9 secretion.
Zufeng Ding, Xianwei Wang, Shijie Liu, Sichang Zhou, Rajshekhar A Kore, Shengyu Mu, Xiaoyan Deng, Yubo Fan, Jawahar L Mehta. Theranostics 2020
25
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.